Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07043270 · ClinicalTrials.gov registry record · Phase 2
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
A Phase 2 study of Pancreas Adenocarcinoma, sponsored by Dartmouth-Hitchcock Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT07043270 is a Phase 2 study of Pancreas Adenocarcinoma that is actively recruiting participants, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 35 participants, below the 76-participant average among 10 other Pancreas Adenocarcinoma trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07043270, a Phase 2 study of Pancreas Adenocarcinoma, is actively recruiting participants, sponsored by Dartmouth-Hitchcock Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to study the effects and safety of alternating neoadjuvant chemotherapy on borderline resectable pancreatic cancer.
Conditions Studied
Interventions
- DRUG Nab-paclitaxel + Gemcitabine
- DRUG modified FOLFIRINOX (mFOLFIRINOX)
Study Locations (1)
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2029-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07043270
The ClinicalTrials.gov registry entry for NCT07043270 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 76-participant average among 10 other Pancreas Adenocarcinoma trials with a reported enrollment target (54% lower). The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreas Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Nab-paclitaxel + Gemcitabine is the first listed.
NCT07043270 reports 1 study location spanning 1 distinct geographic area - top geographies include New Hampshire.
Frequently Asked Questions
What is clinical trial NCT07043270 about?
NCT07043270 is a clinical study titled "24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC". The purpose of this research is to study the effects and safety of alternating neoadjuvant chemotherapy on borderline resectable pancreatic cancer.
What is the current status of trial NCT07043270?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2025-09-29. Estimated completion is 2029-07-01.
What conditions does trial NCT07043270 study?
This clinical trial studies the following conditions: Pancreas Adenocarcinoma.
What interventions are being tested in trial NCT07043270?
The interventions under investigation include: Nab-paclitaxel + Gemcitabine (DRUG), modified FOLFIRINOX (mFOLFIRINOX) (DRUG).
Who is sponsoring clinical trial NCT07043270?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07043270 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
RECRUITING · Phase 2
-
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
RECRUITING · Phase 2
-
Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
ACTIVE NOT RECRUITING · Phase 2
-
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.